Alzheimer’s Disease Serum

About Alzheimer’s Disease Serum

Alzheimer’s Disease Serum for Neurodegeneration and Biomarker Research

Our Alzheimer’s Disease Serum is sourced from IRB-consented donors clinically diagnosed with Alzheimer’s disease. Each sample is processed and frozen within 24 hours of collection to preserve proteins and other labile analytes. Alzheimer’s disease is a progressive neurodegenerative disorder characterised by extracellular amyloid-beta plaques, intracellular hyperphosphorylated tau tangles, synaptic and neuronal loss, and reactive astrogliosis and microglial activation.

Neurodegeneration Biology and Blood-Based Markers

• Amyloid-beta: the Abeta42/Abeta40 ratio reflects cerebral amyloid deposition and is a core component of blood-based biomarker research.
• Phosphorylated tau: p-tau181 and p-tau217 track tau pathology and are the most discriminating blood analytes currently in use, with p-tau217 showing the strongest performance.
• Neurofilament light chain (NfL) is a general marker of axonal injury and neurodegeneration, elevated across many neurological diseases rather than specific to Alzheimer’s.
• GFAP reflects reactive astrogliosis and rises early in the disease course, complementing amyloid and tau readouts.
• APOE genotype is the strongest common genetic risk factor and is a standard stratification variable in biomarker cohorts.
• Matrix caveat, stated honestly: for p-tau and amyloid assays, plasma is the better-validated matrix and is what most published blood-based biomarker work uses. Serum is appropriate for many protein, metabolomic, and comorbidity analyses and for cross-matrix method comparison, but performance of p-tau assays in serum should be established for your platform rather than assumed. Our Alzheimer’s Disease Plasma and Alzheimer’s Disease Cerebrospinal Fluid products are better suited to core amyloid and tau biomarker work.

Donor Stratification Available

• Disease stage: mild cognitive impairment, mild, moderate, or severe dementia
• Cognitive assessment scores (MMSE, MoCA, or CDR) where documented
• APOE genotype where available
• Age at onset, including early-onset donors
• Treatment status: cholinesterase inhibitors, memantine, anti-amyloid monoclonal antibody therapy, or treatment-naive
• Comorbid cerebrovascular disease, type 2 diabetes, or depression
• Age- and sex-matched cognitively unimpaired controls available

Product Features

• Collected from clinically confirmed Alzheimer’s disease donors
• Research Use Only (RUO)
• Processed and frozen within 24 hours of collection
• IRB-approved protocols with documented consent
• Custom aliquot volumes available upon request

De-identified Donor Data

• Diagnosis confirmation
• Age, sex assigned at birth, and race/ethnicity
• Cognitive assessment scores and disease stage where available
• Donor-reported medications, allergy and infectious disease history, and comorbidities
• Additional Alzheimer’s disease-specific metadata available on request

Applications

• Neurodegeneration biomarker discovery and validation
• Cross-matrix method comparison for amyloid, p-tau, NfL, and GFAP assays
• Neuroinflammation and complement pathway profiling
• Serum proteomic and metabolomic studies
• Genotype-stratified biomarker analysis, including APOE
• Vascular and metabolic comorbidity research in dementia cohorts
• Assay development, reference-range, and platform validation work
• Therapeutic candidate screening and treatment-response research

Other Alzheimer’s Disease Specimen Types

Alzheimer’s disease donor material is also available as Alzheimer’s Disease Plasma, Alzheimer’s Disease PBMC, Alzheimer’s Disease Whole Blood, and Alzheimer’s Disease Cerebrospinal Fluid.

Compliance and Quality Assurance

• IRB-approved and HIPAA-compliant protocols
• Electronic informed consent with 21 CFR Part 11 – compliant e-signatures
• Documentation support available for regulatory review

Ordering & Customization

Alzheimer’s disease serum is available in standard and custom volumes. For pricing, international orders, or documentation requirements, please email learnmore@sanguinebio.com to ensure compatibility with your country’s regulations. For the full specimen range, see our human serum collection.